 |
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||
 |
||||||
 |
|
|
||||
|
||||||
 |
|
Scientific Advisory Board Marc K. Hellerstein, MD, PhD Nicholas Chiorazzi, MD
William Evans, PhD
Samuel Klein, M.D.
Dale Johnson, PharmD, PhD
Leonard Makowka, MD, PhD Manoj C. Desai, PhD
Business Advisory Board Frederick Frank Sally Anne Lynch, PhD Mary Tanner
Jerry Treppel Susan Clymer Biographies of the Scientific Advisory Board Nicholas Chiorazzi, MD CEO, North Shore-Long Island Jewish Research Institute Professor of Medicine, New York University School of Medicine William Evans, PhD Professor, Donald W. Reynolds Center on Aging University of Arkansas School of Medicine From 1993 to 1997, Dr. Evans was the director of the Noll Physiological Research Center at the Pennsylvania State University, and from 1982 to 1993, he served as the Chief of the Human Physiology Laboratory at the U.S.D.A. Human Nutrition Research Center on Aging at Tufts University. He is a Fellow of the American College of Sports Medicine, The American College of Nutrition, and an honorary member of the American Dietetic Association. He is the author or co-author of more than 160 publications in scientific journals. His laboratory examines the relationship between exercise, nutrition and aging. His landmark studies have demonstrated the ability of older men and women to improve strength, fitness, and health through exercise, even into the 10th decade of life. He has served as an expert advisor to NASA in a number of committees, including the Science Working Group responsible for the design of the Human Research Facility aboard the International Space Station and The Life Sciences Advisory Subcommittee. He also served at the head of the Nutrition and Exercise research group for the National Space Biomedical Institute. Samuel Klein, MD Danforth Professor and Director Center for Human Nutrition Washington University Dr. Klein is the director of the Washington University Center for Human Nutrition, associate program director of the General Clinical Research Center, and medical director of the Barnes-Jewish Hospital Nutrition Support Service. He is also a professor of medicine at Washington University School of Medicine in St. Louis. He received his MD from Temple University Medical School, and an MS in nutritional biochemistry and metabolism from the Massachusetts Institute of Technology. He completed his residency training in internal medicine and a clinical nutrition fellowship at University Hospital in Boston. He also completed a nutrition research fellowship at Harvard Medical School in Boston and a gastroenterology fellowship at the Mount Sinai Hospital in New York. Dr. Klein's primary research is focused on the regulation of metabolism, particularly lipid metabolism in obesity. Dale Johnson, PharmD, PhD President, Emilien, Inc. Dr. Johnson is a founder and president and CEO of Emiliem, Inc., a biotechnology company in the San Francisco Bay Area that focuses on creating new oncology therapeutics. He has over 25 years of experience in biotechnology and pharmaceutical research and development activities, in which he has led and managed groups ranging from small units in start-up companies to multinational units in large corporations. Dr. Johnson has participated in the research and development of over 100 compounds of which 15 have become marketed healthcare medicinal products in the United States and Europe. Most recently, he served as vice president, drug assessment & cevelopment at Chiron Corporation and previously as vice president, preclinical development. Prior research and development positions include Hoechst-Roussel Pharmaceuticals, Inc., International Research and Development Corp. (a preclinical CRO), Lederle (American Cyanamid), and Eos Biotechnology. Dr. Johnson received his PhD in toxicology from the University of Michigan where he was awarded an AFPE Fellowship. Before his PhD studies, he received a BS and a PharmD from the University of Michigan and completed a clinical pharmacy residency at UM Medical Center where he was awarded the National Resident of the Year Award. He is a diplomate of the American Board of Toxicology and serves as a member of industry and government advisory boards. Dr. Johnson is co-editor of the journals The Chemistry of Metabolic and Toxicological Processes and Current Opinion in Drug Discovery & Development and is an adjunct professor in molecular toxicology at University of California, Berkeley, where he teaches computational toxicology. Leonard Makowka, MD, PhD Co-Founder Tractus Medical, Inc. Manoj C. Desai, PhD Vice President, Medicinal Chemistry Gilead Sciences, Inc. Business Advisory Board Sally Anne Lynch, PhD PhD Biotechnology Equity Analyst General American Investors Dr. Lynch is a biotechnology equity analyst at General American Investors, a publicly traded closed end mutual fund with assets of $1.2 billion. Approximately 10% of the fund is under Dr. Lynch's management. Dr. Lynch received her PhD in molecular biology from the State University of New York at Stony Brook in 1988 and was a postdoctoral research fellow at Memorial Sloan Kettering Cancer Center, Division of Solid Tumor Immunology from 1988 to 1994. Mary Tanner General Partner Life Science Partners Ms. Tanner is founder and Managing Director of Life Sciences Partners, a healthcare investment and advisory firm. From 2001 to 2004, she was senior managing director at Bear, Stearns & Co., Inc., a financial services company. Before Bear, Stearns, Ms. Tanner was a healthcare consultant from 2000 to 2001 and held various positions at Lehman Brothers Inc., a financial services company, including managing director and head of the health care practice, from 1984 to 2000. She was the first woman managing director at Lehman Brothers. Ms. Tanner received her BA from Harvard. Jerry Treppel General Partner Wheaton Capital Management Mr. Treppel is the general partner of Wheaton HealthCare Partners LP. His previous position was a managing director at Banc America Securities. For the past 15 years, he has analyzed the area of specialty pharmaceuticals and created the first investor conference in the sector. Mr. Treppel has been widely recognized for his expertise in this area, accruing accolades from Reuters, Institutional Investor, and the Wall Street Journal for his excellence in industry knowledge. Susan Clymer Managing Director Nichi Bei Bio Ms. Clymer is the Managing Director and founder of NichiBei Bio, Inc. Ms. Clymer has extensive biopharma business development and deal making experience from more than 25 years of business experience in the U.S. and Japanese biotechnology industries, has overseen multiple M&A deals, and has served on the Board of Directors of several private and public biotechnology companies including Sapient Health Network (acquired by WebMD in 2000), Goulter Medical, and TransMedx. She is currently a Board member of ReqMed, a Japanese life science venture company and Osprey Pharmaceutical, a Canadian bioventure company located in Montreal. Prior to founding Nichi Bei Bio, Ms. Clymer was a Fulbright Scholar in Japan affiliated with the Japan Bioindustry Association (JBA) created by the Ministry of International Trade and Industry and Tokyo University. From 1984 - 1989, Ms. Clymer worked in business development at Scios (formerly California Biotechnology) and Bio-Response (acquired by Baxter Healthcare). From 1978 - 1984 she was an analyst with the U.S. Congressional Office of Technology Assessment (OTA) where she co-authored an in-depth report for Congressman Albert Gore Jr. on Japan's competitive position in biotechnology. |
|